This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William Egan, PhD; Carl E. Frasch, PhD; Bascom F. Anthony, MD

JAMA. 1995;273(11):888-889.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the United States, vaccines are licensed by the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration on the basis of their demonstrated safety and efficacy and the demonstrated ability of the manufacturer to produce a consistent product. After licensure, vaccines are generally released to the market on a lot-by-lot basis, following CBER's review of lot-release testing results. A lot is released only if it meets all predefined specifications. A discussion of US vaccine regulation was published recently by Parkman and Hardegree.¹

See also p 849.

As reported in this issue of THE JOURNAL,² during studies of the interchangeability of licensed Haemophilus influenzae type b (Hib) polysaccharide-protein conjugate vaccines, Anderson et al found that a lot of Hib vaccine with the capsular polysaccharide conjugated to the meningococcal outer membrane protein complex (PedvaxHib, Merck and Co, West Point, Pa) produced lower than expected immune . . . [Full Text PDF of this Article]

Author Affiliations
From the Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Md.

Footnotes
Reprint requests to the Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448 (Dr Egan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?